Myomo, Inc., a wearable medical robotics company specializing in myoelectric braces for individuals with neuromuscular disorders, reported a significant increase in revenue for the fiscal year ending December 31, 2025. The company generated total revenue of $40.9 million, a 26% increase from $32.6 million in 2024. This growth was primarily driven by a higher number of revenue units sold and an increase in the average selling price. Despite this revenue growth, Myomo incurred a net loss of $15.6 million, compared to a loss of $6.2 million in the previous year, reflecting ongoing investments in research and development, as well as increased selling and marketing expenses.
The company's direct billing channel, which accounted for 74% of total revenue, saw a 20% increase to $30.4 million, while international sales rose by 48% to approximately $6.8 million. However, revenues from the Veterans Administration (VA) decreased by 31% to $0.8 million. Myomo's gross margin also declined to 65.7% from 71.2% in 2024, attributed to higher warranty expenses and changes in overhead costs. The company anticipates improvements in gross margin in 2026 due to increased volume and cost reduction initiatives.
In terms of strategic developments, Myomo has focused on expanding its MyoConnect referral program and increasing sales through orthotics and prosthetics (O&P) providers. The company has also made significant strides in international markets, obtaining necessary certifications to market its products in Europe and Canada. However, Myomo faces challenges related to reimbursement policies from Medicare and other payers, which could impact future revenue growth. The company has entered into a Loan and Security Agreement with Avenue Capital Management, providing $17.5 million in funding to support its operations and growth initiatives.
As of December 31, 2025, Myomo employed 194 full-time employees and reported a working capital of approximately $19.2 million. The company is committed to investing in research and development to enhance its product offerings, including the anticipated launch of the MyoPro3. Myomo's outlook remains cautious, as it continues to navigate the complexities of the healthcare reimbursement landscape and the competitive market for medical devices. The company aims to achieve cash flow breakeven while expanding its market presence and improving operational efficiencies.
About MYOMO, INC.
Myomo, Inc. develops wearable robotic devices, primarily the MyoPro upper limb orthosis, to assist individuals with neuromuscular disorders and paralysis. The company’s products leverage patented EMG control technology to enable users to regain arm and hand function. Serving healthcare providers, insurance payers, and international markets, Myomo focuses on innovative, custom-fabricated solutions that improve independence and quality of life for patients with neurological impairments.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.